CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oragenics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oragenics Inc
1990 MAIN STREET, SUITE 750
Phone: (813) 286-7900p:813 286-7900 SARASOTA, FL  34236  United States Ticker: OGENOGEN
Business Summary
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product NT-CoV2-1 is an intranasal vaccine candidate to prevent coronavirus disease (COVID-19) from the SARS-CoV-2 virus and variants thereof. Its lantibiotics program features a novel class of antibiotics against bacteria its research has shown may be applicable to multiple antibiotic-resistant organisms. Its Antibiotics product is a semi-synthetic analog of MU1140, which is a member of lantibiotic class of antibiotics. Its product pipeline also includes ONP-002, which is a fully synthetic neurosteroid being developed to treat mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC). Through its wholly owned subsidiary, Noachis Terra, is engaged in the research and development stage for its new Terra CoV-2 and NT-CoV2-1 vaccine product candidates.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Executive Chairman of the Board Charles L.Pope 72 2/12/2024 6/4/2010
President, Interim Principal Executive Officer MichaelRedmond 2/12/2024 1/1/2023
Chief Financial Officer, Treasurer, Secretary JanetHuffman 51 3/7/2023 3/7/2023
7 additional Officers and Directors records available in full report.

Business Names
Business Name
iviGene Corporation
Noachis Terra Inc.
OGEN
4 additional Business Names available in full report.

General Information
Number of Employees: 5 (As of 12/31/2023)
Outstanding Shares: 4,480,693 (As of 3/26/2024)
Shareholders: 40
Stock Exchange: ASE
Federal Tax Id: 593410522
Fax Number: (813) 286-7904


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024